Type 2 Diabetes Mellitus Completed Phase Trials for Insulin Aspart (DB01306)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01022658INSUlin Regimens and VASCular FunctionsTreatment
NCT02419859A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes MellitusTreatment
NCT02230618Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
NCT00659282Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
NCT00755833Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months
NCT00709683Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®
NCT00715663Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes
NCT00715780Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
NCT00657319Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
NCT01486875Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
NCT00676741Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
NCT01487421An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime
NCT01487408Special Survey for Type 1 or Type 2 Diabetic Patients
NCT01487382Special Survey for Paediatric Subjects
NCT00789711An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes
NCT01487369Special Survey of Production of Insulin Aspart Specific Antibody
NCT01542060Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
NCT01538576Paediatric Subjects - Special Survey
NCT01538589Special Survey for Patients With Type 1 or Type 2 Diabetes
NCT01536600Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes
NCT01536639Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes
NCT01536613Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
NCT01536652Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes
NCT01548248Efficacy and Safety of Levemir® Used as Basal Insulin
NCT01542424An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
NCT01542489Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
NCT01548235Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment
NCT01565733Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes
NCT01536626Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands
NCT00869908Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
NCT00834262Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients
NCT00842894Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
NCT00699179Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
NCT00771680Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
NCT00696163Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
NCT00696995An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment
NCT00698269An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
NCT00698126Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes
NCT00737776Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes
NCT00729898Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
NCT00670722Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
NCT00671008Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
NCT00675493Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30
NCT00675220Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™
NCT00700648An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
NCT00704223Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
NCT00775736Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin
NCT02036372Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes MellitusTreatment